Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
characterized
by
the
presence
of
at
least
one
cardiovascular
(CVD)
risk
factor,
underscoring
its
potential
to
elevate
CVD
in
affected
individuals.
However,
evidence
linking
MASLD
subclinical
coronary
atherosclerosis
remains
scarce,
and
further
investigations
are
necessary
elucidate
independent
role
varying
severities
as
a
factor.
This
study
analyzed
7,507
participants
aged
≥
40
who
underwent
comprehensive
health
evaluations
Shanghai
Health
Medical
Center.
Logistic
regression
analysis
was
utilized
explore
relationship
between
severity
artery
calcification
(CAC).
Correlation
performed
assess
association
CAC
staging.
After
adjusting
for
established
factors,
showed
significant
with
CAC,
which
intensified
increasing
severity.
Among
individuals
hypertension,
markedly
correlated
CAC.
In
contrast,
non-hypertensive
participants,
only
moderate
severe
were
significantly
associated
while
mild
demonstrated
no
notable
link,
even
after
adjustment
factors.
Moreover,
correlation
revealed
positive
staging,
indicating
that
higher
aligned
more
advanced
stages.
highlighted
independently
atherosclerosis,
irrespective
traditional
an
urban
eastern
Chinese
population
without
prior
history
atherosclerosis.
The
strongest
associations
observed
MASLD,
emphasizing
importance
assessing
stratification.
Gastroenterology,
Journal Year:
2024,
Volume and Issue:
167(4), P. 689 - 703
Published: April 29, 2024
Hepatocellular
carcinoma
(HCC)
is
a
leading
cause
of
cancer
death.
HCC
preventable
with
about
70%
attributable
to
modifiable
risk
factors.
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs),
Food
and
Drug
Administration-approved
medications
for
treating
type
2
diabetes
mellitus
(T2DM),
have
pleiotropic
effects
on
counteracting
factors
HCC.
Here
we
evaluate
the
association
GLP-1RAs
incident
in
real-world
population.
Journal of clinical lipidology,
Journal Year:
2024,
Volume and Issue:
18(3), P. e320 - e350
Published: April 24, 2024
BACKGROUNDThis
joint
expert
review
by
the
Obesity
Medicine
Association
(OMA)
and
National
Lipid
(NLA)
provides
clinicians
an
overview
of
pathophysiologic
clinical
considerations
regarding
obesity,
dyslipidemia,
cardiovascular
disease
(CVD)
risk.METHODSThis
is
based
upon
scientific
evidence,
perspectives
authors,
peer
OMA
NLA
leadership.RESULTSAmong
individuals
with
adipose
tissue
may
store
over
50%
total
body
free
cholesterol.
Triglycerides
represent
up
to
99%
lipid
species
in
tissue.
The
potential
for
expansion
accounts
greatest
weight
variance
among
most
individuals,
percent
fat
ranging
from
less
than
5%
60%.
While
population
studies
suggest
a
modest
increase
blood
low-density
lipoprotein
cholesterol
(LDL-C)
levels
excess
adiposity,
adiposopathic
dyslipidemia
pattern
often
described
adiposity
includes
elevated
triglycerides,
reduced
high
density
(HDL-C),
increased
non-HDL-C,
apolipoprotein
B,
LDL
particle
concentration,
small,
dense
particles.CONCLUSIONSObesity
increases
CVD
risk,
at
least
partially
due
promotion
adiposopathic,
atherogenic
profile.
also
worsens
other
cardiometabolic
risk
factors.
Among
patients
interventions
that
reduce
improve
outcomes
are
generally
associated
improved
levels.
Given
improvement
LDL-C
reduction
overweight
or
early
treat
both
(LDL-C
and/or
non-HDL-C)
priorities
reducing
CVD.
This
risk.
leadership.
particles.
Obesity Pillars,
Journal Year:
2024,
Volume and Issue:
10, P. 100108 - 100108
Published: March 12, 2024
This
joint
expert
review
by
the
Obesity
Medicine
Association
(OMA)
and
National
Lipid
(NLA)
provides
clinicians
an
overview
of
pathophysiologic
clinical
considerations
regarding
obesity,
dyslipidemia,
cardiovascular
disease
(CVD)
risk.
is
based
upon
scientific
evidence,
perspectives
authors,
peer
OMA
NLA
leadership.
Among
individuals
with
adipose
tissue
may
store
over
50%
total
body
free
cholesterol.
Triglycerides
represent
up
to
99%
lipid
species
in
tissue.
The
potential
for
expansion
accounts
greatest
weight
variance
among
most
individuals,
percent
fat
ranging
from
less
than
5%
60%.
While
population
studies
suggest
a
modest
increase
blood
low-density
lipoprotein
cholesterol
(LDL-C)
levels
excess
adiposity,
adiposopathic
dyslipidemia
pattern
often
described
adiposity
includes
elevated
triglycerides,
reduced
high
density
(HDL-C),
increased
non-HDL-C,
apolipoprotein
B,
LDL
particle
concentration,
small,
dense
particles.
increases
CVD
risk,
at
least
partially
due
promotion
adiposopathic,
atherogenic
profile.
also
worsens
other
cardiometabolic
risk
factors.
patients
interventions
that
reduce
improve
outcomes
are
generally
associated
improved
levels.
Given
improvement
LDL-C
reduction
overweight
or
early
treat
both
(LDL-C
and/or
non-HDL-C)
priorities
reducing
CVD.
Liver International,
Journal Year:
2024,
Volume and Issue:
44(10), P. 2538 - 2550
Published: July 1, 2024
We
examined
the
impact
of
a
co-diagnosis
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
and
type
2
diabetes
(T2D)
on
patient
outcomes.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(14), P. 2220 - 2220
Published: July 11, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
common
long-lasting
that
affects
millions
of
people
around
the
world.
It
best
identified
with
hepatic
fat
build-up
ultimately
leads
to
inflammation
and
damage.
The
classification
nomenclature
NAFLD
have
long
been
controversial
topic,
until
2020
when
group
international
experts
recommended
substituting
MAFLD
(metabolic
dysfunction-associated
FLD).
was
then
terminologically
complemented
in
2023
by
altering
it
MASLD,
i.e.,
metabolic
steatotic
(MASLD).
Both
MASLD
terminologies
comprise
element
disorder,
as
they
offer
diagnostic
benchmarks
are
embedded
risk
factors
underlie
disease.
(as
multisystemic
disease)
provides
comprehensive
definition
includes
larger
population
patients
who
at
morbidity
mortality,
well
adverse
cardiovascular
diabetes
outcomes.
highlights
risks
lean
or
normal
weight
individuals,
factor
has
not
accentuated
discussed
previous
guidelines.
Novel
antihyperglycemic
agents,
anti-hyperlipidemic
drugs,
lifestyle
modifications,
nutritional
interventions,
exercise
therapies
extensively
studied
MASLD.
Nutrition
plays
vital
role
managing
both
conditions,
where
centralizing
on
diet
rich
whole
vegetables,
fruits,
foods,
healthy
fats,
proteins,
specific
nutrients
(e.g.,
omega-3
acids
fibers)
can
improve
insulin
resistance
reduce
inflammation.
Thus,
essential
understand
nutrition
these
conditions
work
develop
an
individualized
plan
for
optimal
health.
This
review
discusses
prevention
strategies
NAFLD/MAFLD/MASLD
management,
particular
attention
correction.
Current Obesity Reports,
Journal Year:
2025,
Volume and Issue:
14(1)
Published: Jan. 11, 2025
This
narrative
review
explores
the
role
of
Medical
Nutritional
Therapy
(MNT)
in
managing
Metabolic-Associated
Steatotic
Liver
Disease
(MASLD),
previously
known
as
nonalcoholic
fatty
liver
disease.
It
aims
to
examine
effectiveness
specific
nutritional
strategies
preventing
and
treating
this
obesity-linked
Emerging
evidence
underscores
benefits
Mediterranean
diet,
low-carbohydrate
diets,
intermittent
fasting
reducing
fat,
improving
insulin
sensitivity,
mitigating
inflammation.
Supplementing
with
vitamin
E,
omega-3
acids,
silymarin
can
potentially
reduce
fibrosis
promote
health.
MNT
is
a
key
intervention
for
MASLD
management,
emphasizing
dietary
patterns,
caloric
restriction,
nutraceutical
supplementation.
Integrating
these
lifestyle
modifications,
including
regular
physical
activity,
offers
comprehensive
approach
metabolic
outcomes
patients
MASLD.
Further
research
needed
refine
personalize
therapeutic
interventions.
ABSTRACT
Background
The
continuum
of
metabolic
syndrome
encompasses
a
spectrum
dysfunctions
impacting
obesity‐linked
insulin
resistance,
glucose
homeostasis,
lipid
metabolism
and
pro‐inflammatory
immune
responses.
global
prevalence
diseases,
including
diabetes,
chronic
liver
disease,
cardiometabolic
disease
kidney
has
surged
in
recent
decades,
contributing
significantly
to
population
mortality.
Metabolic
dysfunction‐associated
steatotic
(MASLD),
formerly
known
as
non‐alcoholic
fatty
is
leading
cause
worldwide.
MASLD
poses
significant
health
challenge
with
its
rising
prevalence,
placing
substantial
burden
on
healthcare
systems,
impacts
patient
well‐being
incurs
economic
costs.
Addressing
requires
comprehensive
understanding
interconnected
factors,
implications.
Lack
awareness,
imprecise
non‐invasive
diagnostic
methods
ineffective
preventive
interventions
are
core
components
the
MASLD‐related
problem.
Aim
aim
this
article
was
summarise
from
payer's
perspective.
Methods
We
carried
out
review
MASLD.
These
topics
led
discussions
insights
by
an
expert
panel
during
7th
Continuum
Roundtable
meeting,
which
took
place
November
2023.
This
meeting
focused
burden,
patient‐reported
outcomes
economics,
payor
societal
perspectives,
aimed
identify
opportunities
for
improving
care,
optimise
resource
allocation
mitigate
overall
impact
individuals
society
related
During
roundtable,
emphasis
emerged
need
greater
awareness
strategic
deployment
diagnostic,
therapeutic
preventative
measures
address
effectively.
Conclusion
high
growing.
Prioritising
prevention
dysregulation
timely
can
yield
holistic
strategy
combat
MASLD,
progression
potentially
lower
Trial
Registration:
NCT06309992
Diagnostics,
Journal Year:
2025,
Volume and Issue:
15(3), P. 252 - 252
Published: Jan. 22, 2025
In
recent
years,
novel
findings
have
progressively
and
promisingly
supported
the
potential
role
of
Artificial
intelligence
(AI)
in
transforming
management
various
neoplasms,
including
hepatocellular
carcinoma
(HCC).
HCC
represents
most
common
primary
liver
cancer.
Alarmingly,
incidence
is
dramatically
increasing
worldwide
due
to
simultaneous
“pandemic”
spreading
metabolic
dysfunction-associated
steatotic
disease
(MASLD).
MASLD
currently
constitutes
leading
cause
chronic
hepatic
damage
(steatosis
steatohepatitis),
fibrosis,
cirrhosis,
configuring
a
scenario
where
an
onset
has
been
reported
even
early
stage.
On
other
hand,
serious
plague,
significantly
burdening
outcomes
hepatitis
B
(HBV)
C
(HCV)
virus-infected
patients.
Despite
progress
this
cancer,
overall
prognosis
for
advanced-stage
patients
continues
be
poor,
suggesting
absolute
need
develop
personalized
healthcare
strategies
further.
“cold
war”,
machine
learning
techniques
neural
networks
are
emerging
as
weapons,
able
identify
patterns
biomarkers
that
would
normally
escaped
human
observation.
Using
advanced
algorithms,
AI
can
analyze
large
volumes
clinical
data
medical
images
(including
routinely
obtained
ultrasound
data)
with
elevated
accuracy,
facilitating
diagnosis,
improving
performance
predictive
models,
supporting
multidisciplinary
(oncologist,
gastroenterologist,
surgeon,
radiologist)
team
opting
best
“tailored”
individual
treatment.
Additionally,
contribute
enhancing
effectiveness
metabolomics–radiomics-based
promoting
identification
specific
HCC-pathogenetic
molecules
new
targets
realizing
therapeutic
regimens.
era
precision
medicine,
integrating
into
routine
practice
appears
promising
frontier,
opening
avenues
cancer
research
Medicina,
Journal Year:
2025,
Volume and Issue:
61(2), P. 192 - 192
Published: Jan. 22, 2025
The
purpose
of
this
article
is
to
present
selected
food
additives
as
disruptors
normal
intestinal
homeostasis
with
a
potential
impact
on
the
development
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD).
A
comprehensive
literature
search
was
conducted
in
three
major
electronic
databases:
PubMed,
ScienceDirect,
and
Google
Scholar.
MASLD
prevalent
condition
that
closely
related
global
rise
obesity.
Its
pathogenesis
multifactorial,
genetic,
environmental,
factors
playing
key
role.
“multiple-hit”
hypothesis
suggests
Western-style
diet,
rich
ultra-processed
foods,
saturated
fats,
additives,
combined
low
physical
activity,
contributes
obesity,
which
promotes
lipid
accumulation
liver.
Recent
studies
underscore
role
impaired
MASLD.
Food
including
preservatives,
emulsifiers,
sweeteners,
affect
gut
health
function.
Selected
preservatives
inhibit
pathogenic
microorganisms
but
disrupt
microbiota,
leading
changes
permeability
dysfunction.
Some
emulsifiers
thickeners
can
cause
inflammation
alter
microbiome,
contributing
steatosis.
Furthermore,
use
sweeteners
such
sucralose
aspartame
has
been
linked
metabolism
microbial
composition,
turn
disorders.